Stock UBX UNITY BIOTECHNOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Unity Biotechnology, Inc. Stock

Equities

UBX

US91381U2006

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.5 USD +1.35% Intraday chart for Unity Biotechnology, Inc. 0.00% -22.28%
Apr. 23 Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment MT
Apr. 23 Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME CI

Financials (USD)

Sales 2024 * - Sales 2025 * - Capitalization 24.84M
Net income 2024 * -41M Net income 2025 * -36M EV / Sales 2024 * -
Net cash position 2024 * 8.44M Net Debt 2025 * 17.76M EV / Sales 2025 * -
P/E ratio 2024 *
-0.61 x
P/E ratio 2025 *
-0.74 x
Employees 19
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.75%
More Fundamentals * Assessed data

Chart Unity Biotechnology, Inc.

Dynamic Chart

Latest news about Unity Biotechnology, Inc.

Unity Biotechnology Adds More Patients, Extends Length of Trial of Prospective Macular Edema Treatment MT
Unity Biotechnology, Inc. Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME CI
HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating MT
Unity Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Unity Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Seen -2- DJ
North American Morning Briefing : Markets Steady -2- DJ
Unity Biotechnology, Inc. Announces New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-Lasting, Disease-Modifying Intervention in Vision Loss CI
Unity Biotechnology, Inc. Doses First Patients in Phase 2 Aspire Study of Ubx1325 in DME CI
North American Morning Briefing : Stocks Futures -2- DJ
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2 MT
Unity Biotechnology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Sector Update: Health Care Stocks Rising Late Afternoon MT
Sector Update: Health Care MT
Unity Biotechnology Agrees to Exercise Warrants for $4.38 Million in Gross Proceeds; Shares Fall MT
More news

Latest transcript on Unity Biotechnology, Inc.

Logo Unity Biotechnology, Inc.
Unity Biotechnology, Inc. - Special Call
More transcripts

Analyst Recommendations on Unity Biotechnology, Inc.

HC Wainwright Adjusts Unity Biotechnology Price Target to $8 From $10, Maintains Buy Rating MT
Wedbush Upgrades Unity Biotechnology to Outperform From Neutral, Says Remains in Execution Mode With Advancement of UBX1325; Raises PT to $4 From $2 MT
Wedbush Downgrades Unity Biotechnology to Neutral From Outperform, Notes Limited Cash Runway, Lack of Other Near-Term Value-Driving Catalysts; Trims PT to $2 From $3 MT
Roth MKM Initiates Unity Biotechnology at Buy With $10 Price Target MT
Citigroup Adjusts Price Target on Unity Biotechnology to $6 From $5, Maintains Buy Rating MT
More recommendations

Press releases Unity Biotechnology, Inc.

UNITY Biotechnology Announces Upcoming Presentations at the ARVO 2024 Annual Meeting AQ
UNITY Biotechnology Announces Extension of Phase 2b ASPIRE Clinical Study Evaluating UBX1325 in DME AQ
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates AQ
New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss AQ
UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME AQ
More press releases

Quotes and Performance

1 day+0.34%
1 week-1.99%
Current month-9.76%
1 month-6.33%
3 months-12.94%
6 months-9.76%
Current year-23.32%
More quotes

Highs and lows

1 week
1.46
Extreme 1.46
1.52
1 month
1.46
Extreme 1.46
1.67
Current year
1.46
Extreme 1.46
2.02
1 year
1.46
Extreme 1.46
3.82
3 years
1.46
Extreme 1.46
53.00
5 years
1.46
Extreme 1.46
154.40
10 years
1.46
Extreme 1.46
245.60
More quotes

Managers and Directors - Unity Biotechnology, Inc.

Managers TitleAgeSince
Anirvan Ghosh CEO
 Chief Executive Officer 60 20-03-29
Nathaniel E. David FOU
 Founder 56 09-03-29
Lynne Sullivan DFI
 Director of Finance/CFO 58 20-07-31
Members of the board TitleAgeSince
Paul Berns BRD
 Director/Board Member 57 18-03-26
Camille D. Samuels BRD
 Director/Board Member 52 15-02-28
Keith Leonard CHM
 Chairman 62 15-12-31
More insiders

Quotes

Date Price Change Volume
24-04-26 1.5 +1.35% 38 492
24-04-25 1.48 +0.68% 17,141
24-04-24 1.47 -1.34% 82,056
24-04-23 1.49 +0.68% 36,550
24-04-22 1.48 -1.33% 71,949

Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT

More quotes

Company Profile

Unity Biotechnology, Inc. is engaged in developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells. The Company is also focused on advancing senolytic programs primarily in ophthalmologic disorders. It is also focused on advancing other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/vascular endothelial growth factor (VEGF) bispecific to treat vascular eye disease. The Company's UBX1325 and UBX1967 are designed to inhibit the function of proteins that senescent cells rely on for survival. UBX1325 is an advanced drug candidate for age-related diseases of the eye, including diabetic macular edema (DME), age-related macular degeneration, (AMD), and diabetic retinopathy (DR). Its UBX2050 is an investigational, fully human anti-Tie2 agonist monoclonal antibody.
Sector
Biotechnology & Medical Research
Calendar
2024-05-06 - Q1 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.48 USD
Average target price
6 USD
Spread / Average Target
+305.41%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
UNITY BIOTECHNOLOGY, INC. Stock Unity Biotechnology, Inc.
-23.32% 24.84M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.26% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.41% 95.71B
ARGENX SE Stock argenx SE
-0.06% 22.02B
BIONTECH SE Stock BioNTech SE
-17.84% 20.9B
GENMAB A/S Stock Genmab A/S
-9.21% 17.85B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.83% 16.21B
BEIGENE, LTD. Stock BeiGene, Ltd.
-17.63% 15.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+4.55% 13.86B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.11% 12.04B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. UBX Stock